Reliable diagnosis of nigrostriatal degeneration by dopamine transporter SPECT despite drug interaction with venlafaxine or bupropion
European Journal of Nuclear Medicine and Molecular Imaging · 2025
DOI: 10.1007/s00259-024-06989-z ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Ivayla Apostolova und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. Hauptthemen laut MEDLINE: Dopamine Plasma Membrane Transport Proteins, Tomography, Emission-Computed, Single-Photon, Venlafaxine Hydrochloride, Bupropion. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Hamburg-Eppendorf (UKE).
Abstract (Originalsprache)
Purpose
This study examined the impact of venlafaxine and bupropion on the detection of nigrostriatal degeneration by dopamine transporter (DAT)-SPECT.
Methods
43 patients (70.7 ± 8.6y, 44% female) with [ 123 I]FP-CIT-SPECT under venlafaxine ( n = 26, 37.5-225 mg/d), bupropion ( n = 16, 150 or 300 mg/d) or both ( n = 1) were included retrospectively. The striatal specific [ 123 I]FP-CIT binding ratio (SBR), its left–right asymmetry and the putamen-to-caudate ratio were transformed to z-scores and submitted to a cluster analysis for data-driven categorization.
Results
Two clusters were identified. The first cluster (37% cases) showed a Parkinson’s disease (PD)-like pattern: median striatal SBR/asymmetry/putamen-to-caudate z-score -4.5/4.9/-3.8. The second cluster (63%) showed symmetric reduction with normal intra-striatal gradient: median striatal SBR/asymmetry/putamen-to-caudate z-score -2.7/0.4/0.2. Patients with follow-up clinical reference diagnoses of neurodegenerative ( n = 8) and non-neurodegenerative ( n = 16) parkinsonism fell exclusively into the former or the latter cluster, respectively ( p < 0.001).
Conclusion
Venlafaxine and bupropion cause uniform reduction of the striatal [ 123 I]FP-CIT SBR that can be distinguished from PD-like reductions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.
- Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Freiburg, Germany.
- Department of Nuclear Medicine, Medical Center - University of Freiburg, Freiburg, Germany.
- Department of Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. r.buchert@uke.de.
ORCID-Profile: Ralph Buchert
Förderung
- Universitätsklinikum Hamburg-Eppendorf (UKE)
Zitieren
APA
Apostolova, I., Hellwig, S., Karimzadeh, A., Klutmann, S., Meyer, P. T., & Buchert, R. (2025). Reliable diagnosis of nigrostriatal degeneration by dopamine transporter SPECT despite drug interaction with venlafaxine or bupropion. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06989-z
Vancouver
Apostolova I, Hellwig S, Karimzadeh A, Klutmann S, Meyer PT, Buchert R. Reliable diagnosis of nigrostriatal degeneration by dopamine transporter SPECT despite drug interaction with venlafaxine or bupropion. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-024-06989-z
BibTeX
@article{Apostolova2025,
author = {Apostolova, Ivayla and Hellwig, Sabine and Karimzadeh, Amir and Klutmann, Susanne and Meyer, Philipp T and Buchert, Ralph},
title = {Reliable diagnosis of nigrostriatal degeneration by dopamine transporter SPECT despite drug interaction with venlafaxine or bupropion},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
doi = {10.1007/s00259-024-06989-z}
}
EUVIMED